Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage

Neurology
S M DavisRecombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators

Abstract

Although volume of intracerebral hemorrhage (ICH) is a predictor of mortality, it is unknown whether subsequent hematoma growth further increases the risk of death or poor functional outcome. To determine if hematoma growth independently predicts poor outcome, the authors performed an individual meta-analysis of patients with spontaneous ICH who had CT within 3 hours of onset and 24-hour follow-up. Placebo patients were pooled from three trials investigating dosing, safety, and efficacy of rFVIIa (n = 115), and 103 patients from the Cincinnati study (total 218). Other baseline factors included age, gender, blood glucose, blood pressure, Glasgow Coma Score (GCS), intraventricular hemorrhage (IVH), and location. Overall, 72.9% of patients exhibited some degree of hematoma growth. Percentage hematoma growth (hazard ratio [HR] 1.05 per 10% increase [95% CI: 1.03, 1.08; p < 0.0001]), initial ICH volume (HR 1.01 per mL [95% CI: 1.00, 1.02; p = 0.003]), GCS (HR 0.88 [95% CI: 0.81, 0.96; p = 0.003]), and IVH (HR 2.23 [95% CI: 1.25, 3.98; p = 0.007]) were all associated with increased mortality. Percentage growth (cumulative OR 0.84 [95% CI: 0.75, 0.92; p < 0.0001]), initial ICH volume (cumulative OR 0.94 [95% CI: 0.91, 0.97; p < 0.0001...Continue Reading

Citations

Jul 4, 2007·Intensive Care Medicine·Rebecca Appelboam, Elfyn Owen Thomas
Jul 27, 2007·Neuroradiology·Ulla Hedner, Nikolai C Brun
May 31, 2013·Journal of Neural Transmission·J B KuramatsuS Schwab
Feb 2, 2012·International Journal of Computer Assisted Radiology and Surgery·K N Bhanu PrakashWieslaw L Nowinski
May 9, 2012·Current Atherosclerosis Reports·Qingliang T Wang, Stanley Tuhrim
Oct 30, 2008·Current Neurology and Neuroscience Reports·Viktor Szeder, Stephan A Mayer
Apr 29, 2010·Current Neurology and Neuroscience Reports·Holly E HinsonWendy C Ziai
Sep 18, 2010·Current Treatment Options in Neurology·Thomas Mirsen
Jan 25, 2008·Neurocritical Care·Joshua N GoldsteinLee H Schwamm
Mar 25, 2008·Neurocritical Care·Sebastian KochAlejandro A Rabinstein
Aug 29, 2009·Neurocritical Care·Christine A C Wijman
Oct 22, 2009·Neurocritical Care·Michael MoussouttasNeeraj Badjatia
Oct 1, 2010·Neurocritical Care·Michael MoussouttasNeeraj Badjatia
Oct 7, 2011·Neurocritical Care·Michael C ChristensenStephan A Mayer
Sep 12, 2012·Neurocritical Care·Charles M AndrewsScott D Weingart
Aug 7, 2012·Neurocritical Care·Dimitre StaykovRainer Kollmar
Jul 7, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Navdeep Sangha, Nicole R Gonzales
Nov 23, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·W Taylor Kimberly
Dec 6, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·H Bart Brouwers, Joshua N Goldstein
May 16, 2008·The New England Journal of Medicine·Stanley Tuhrim
May 16, 2008·The New England Journal of Medicine·Stephan A MayerUNKNOWN FAST Trial Investigators
Mar 29, 2011·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Guo-qing ZhengJiangang Shen
Oct 13, 2011·Journal of Neurotrauma·Yan-Hua SangRaymond Tak-Fai Cheung
Nov 17, 2007·Critical Care Medicine·Joon-Shik MoonAdnan I Qureshi
Feb 25, 2009·Critical Care Medicine·Robert D Stevens, Anish Bhardwaj
Jan 14, 2010·Critical Care Medicine·Paul Nyquist
Jul 7, 2009·Current Opinion in Critical Care·Craig S Anderson
Dec 21, 2010·Current Opinion in Critical Care·Oliver Flower, Martin Smith
Feb 11, 2012·Current Opinion in Critical Care·Erin M Grise, Opeolu Adeoye
Jan 21, 2012·Journal of Computer Assisted Tomography·Bhanu Prakash KNWieslaw L Nowinski
Aug 23, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J Martí-FàbregasJ-L Martí-Vilalta
Sep 30, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·S Sacco, A Carolei
Feb 25, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M AliUNKNOWN VISTA investigators
Feb 9, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·S TetriM Hillbom
Jan 22, 2008·International Journal of Clinical Practice·A Bhalla, D Hargroves
May 23, 2012·International Journal of Clinical Practice·B R ThanviS K Munshi
May 15, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·M W LorenzC Foerch

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.